Table 1. Mouse characteristics and treatment responses.
| Description | Control | AZD5363 | P-value |
|---|---|---|---|
| No. of Mice | 12 | 12 | |
| Median age (w) | 47.6 | 49.5 | 0.908 |
| range | 42.4-74.5 | 39.0-63.1 | |
| Median initial bodyweight (g) | 36.6 | 35.1 | 0.671 |
| range | 27.6-41.0 | 28.3-53.3 | |
| Median final bodyweight (g) | 34 | 37.2 | 0.353 |
| range | 27.8-49.1 | 29.9-43.3 | |
| Median treatment duration (d) | 25.5 | 38.5 | 0.020 |
| range | 6.0-45.0 | 12.0-75.0 | |
| Median Age at Death (w) | 51.7 | 55.2 | 0.299 |
| range | 43.8-80.0 | 45.3-69.0 | |
| Median OS (d) | 24.0 | 37.0 | 0.016 |
| 95% CI | 12.1-35.9 | 30.2-43.8 | |
| Median PFS (d) | 14 | 28 | 0.010 |
| 95% CI | 7.2-20.8 | 16.1-39.9 | |
| Median GUT weight (g) | 4.3 | 3.6 | 0.840 |
| range | 1.0-17.5 | 1.0-9.2 | |
| Metastatic rate (%) | 50 | 40 | 0.679 |
| frequency | 6/12 | 4/12 | |
| Metastatic Burden (mean no. of mets/mouse) | 2.5 | 2.5 | 1.00 |
| s.e. | 0.8 | 0.6 | |
| Median time to progression P1-P2 (days) | 21.0 | 28.0 | 0.110 |
| range | 3.0-45.0 | 13.0-66.0 | |
| Median time to progression P2-P3 (days) | 8.0 | 19.0 | 0.295 |
| range | 4.0-18 | 7.0-20 | |
| Performance status (% favorable) | 25 | 42 | 0.667 |
| frequency | 3/12 | 5/12 |